tradingkey.logo

Arrowhead Pharmaceuticals Announces Nmpa Approval Of Redemplo® (Plozasiran)

ReutersJan 7, 2026 12:43 PM

- Arrowhead Pharmaceuticals Inc ARWR.O:

  • ARROWHEAD PHARMACEUTICALS ANNOUNCES NMPA APPROVAL OF REDEMPLO® (PLOZASIRAN) FOR FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) IN CHINA

  • ARROWHEAD PHARMACEUTICALS: NMPA APPROVAL TRIGGERS $10 MILLION MILESTONE PAYMENT TO BE PAID BY SANOFI TO ARROWHEAD SUBSIDIARY VISIRNA THERAPEUTICS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI